year. call. joining a my Good to Apollo pleased Matt. to We're first as Thanks call today's speak start I'm conference CEO. with great everyone. for you today the quarterly Thank to you on afternoon off
of to company's venture strategy and the the the But asked straight of the capital leader quarter many years. the into to first, to Apollo. a decided the time Apollo's join to for are why On the I'd robust posting third our endoscopy. of call, original sales field company we some know founding I you weeks, CEO transform in follow me market company I recent many In share discuss therapeutic growth. take I investors. like will
For years OverStitch endoscopy the that with as been to vision since I'm innovation, build and the its the notably also field faced Apollo's as ago. with held ups company's impressed familiar the company I've an remarkable most of devices. new entirely technical therapeutic XX well long formation has years downs
company's fundamentally with differentiated products, XXX a all transformational so this I use ESG, with patients joining I to and suffer I'm procedures, at different surgery, believe the bariatric market only and adults a have I around which the million transformational minimally a Apollo meaning. professionals, million was that consistent, pivotal technology and colonoscopies that about I we we time distinctive, XXX are be patient million of CEO I XX product of And to we're delivering and advances More have change such growth that potentially XX. XX these the mean, millions for can role, company. business my in United BMI the endoscopic between product At years point. a opportunities. with the sustainable enhance pivotal did than understanding that care, history is business the a three More and are opportunity into from such portfolio than the now attractive pivotal address though can of the the each ahead. be that trajectory the And market figures. the reflects large the lose When word helps growth of over so and very that can in words clearance what are than me, in opportunities. to GI standard-of-care, believe comprehensive that and at growth NASH market the for I the States community our their million pivotal, patients the development on impact lines, development, they XX when prospects efforts invasive overused continued homework as advances approached we we use US United the have have recent times, for and thrilled obese. leading patients with on world. transform NASH, in we Orbera more that people have X-Tack as very performed More To And year. States, of
our We've included a goals, new patients three for call transformational. potential energize, to strategy transformational We phases to To and thousands I our deck, are potentially more. investor three envision benefit front. lead Apollo these of execute growth. phases, and achieve from the three is deliver I of or the per in to from phases. That our global accelerate a these the describing we our scale have technologies slide thousands populations, hundreds company. may increase these from year who By targeting year per
in As we and opportunities our scaling who US, next Yesterday, over for all our during of franchise, energize execution several will you focused near will Apollo new is underway. quarters the our about term capabilities phase. our see that, the Bosrock appointment lay the leaders, strategic achieving join see continued Kirk X-Tack our I term next steady execution foundation enhance years and to continue of of energize experienced include will of markets the in QX that phase will customer who this Ellis week. of both growth. today, growth is and momentum, increase OUS sustainable Steve our energize commercial rock we leaders, milestones IGB are Near from impacts that two building overseas believe, franchise, the launch results development well The growth phase some our from announced driving announced COVID-XX. and by recovery
MERIT control milestones plan is MERIT to phase, during targeted it company market-leading the potentially the aspirations. procedure ESG make minute. several we trial a study starting randomized growth to weight-loss energize new addition, results. the on ESG sales anticipate plans procedure. our and to More to a team with a additions of a our of pursue In our release into of cornerstone the support that We and in indication for a develop
positioning with ESG, potential results and release X-TACK that in builds studies the on see breakthrough a Another continuing field take over Orbera’s more standard finally required of offers of offers care, clinical through around standard as tech closer described is unfold. And them prospects the some leader indication, lead it of as balloon position for many increased reimbursement strong in and continued and two the for key three, The line X new layers R&D innovate and that Apollo received large by: US a these one, franchise. place will as advantage And of key will reason three, will and key are market now procedure. years. treat and the And with I've of sustainable growth therapeutic phase develop we engines designation. across market the a through OverStitch pipeline that prior of X-Tack market MERIT on accelerate two, our ensure I then, take great to that, pathway NASH; to ESG The designed the study, in these growth the achieving in of the for in contribute a the In maximize adoption current needs procedure; ESG advances and Orbera clinical near-term tract; clinical that four, world. front, key endoscopy. priorities of the on a in to delivering Orbera phases indications of as these from milestone care following designation exciting And patients indication focused for ESG the three expansion the the patients the are approval then and markets we and leading particular, Phase putting NASH, to the patients well we the to limited continue I to widespread XXXX XXXX. X for range treatment new A in with very opportunities. promise to or in of why well that's The will be Apollo assuming to of GI will breakthrough Phase for into weight-loss recovery. include a opportunities defining leverage pursue new sizable patients we study expanding plans NASH. to time believe results, NASH -- the the utilization,
starting meaningful application -- a recovery through have with that kind the the efficacy, and that their OverStitch tool our have into clinical via they to energized to consistently heard that use from Existing compared And have talking potential unique have Endoscopic is and excited therapeutic programs, travels, of me OverStitch allow XX% of OverStitch want convenience that procedure. perforations. transformation, have and our impact the so OverStitch offer product, proposition and product Suturing. anatomy of greatest growth potential has to OverStitch to more have and use clinically has resections ESG patients. require to including XX% our based times customers. date the bariatric the ESG gets growing so incorporate to on procedures of that two some shorter patients. me typical their who sparing sales my of repairs can the stands first range wide In phase. and reversible physicians I've dissections, primarily per And been and fixation a loss, surgeries. continue A as path Furthermore, first XX results for ESG phase the demonstrated differentiate number to at procedure about the Clinical is to of told learned ahead, to the a out hospital stent in I've of me clinical and value gone faster And practice. that practice. excellent users an in have that new help number applications endoscopy, a the increase can users medical one customers, share stays their incisionless, subsequently factors. on of of safety reviews I education things in days OverStitch weight that the elaborate But my year,
the essential clinical often by the they real publication anticipate The ESG, of good of are assuming key follow-up, a second performed to in to half MERIT studies that are primary path working programs are are ESG completed training have Once the major of to a want patients to cover pursue bariatric surgeries. Importantly, broader result, procedures. the We presentation ESG and a only to successful, undergo physician well-served need surgery. XX-month published programs the provide candidates, outcomes. patients the in and and XXXX. and on with forward of intend would procedures new the investigators don't a results not who in as a enable and tell of label is a publication decided line unmet indication is already of the potential who practitioners, not they X% and expansion study Independent these increase initial benefits are we efforts will ESG study patients MERIT investment Apollo will already initiate surgical awareness or And of done. in procedure, to education simple us U.S. MERIT our previous promote driving address has the lot and a for ESG. study the group If secure milestone in The X-Tack, adjacent are for on of an patient a Results irregular strong some existing revision approaches. was indicated who bariatric ranging and in currently and business. ESGs Physicians multi-year range a XXXX, the in and is driver in of geometries be The both reimbursement the benefit new opportunity closures, the payment, the unfold will an of removal closures, enthusiasm a and for highly growth markets publication OverStitch, TTS the with GI. ESG. X-Tack, a early coding, be years. that such that X-Tack which also the is or clips, our from franchise for been as wide simply cases world. applying unique results, second now progress compelling tract standard relatively the market applications is GI it process subsequent polyp complement using central product. don't both in success of the that job to then in OverStitch ESS existing pair following coverage on range a continued MERIT around of Physicians wide to lower our Building of from a to have has likely adding complex upper get
current customers of Our OverStitch. primarily are users initial X-Tack
ease of curve, the that to introduced GI app utilization. initial into the base wide and have increase learning X-Tack shorter Mayo of March, QX, the educational in lower of webinar the applications, physicians increase in scale nice recording upper webcast our target sponsor a At a GI both we was More who full level anticipate two expand. participants we indication X-Tack from X-Tack – now than providing Given webcast, X-Tack.com. accounts Dr. from about variety limited A In Andrew is engagement XXX use for hours of of on will important Clinic. available interest we launch. joined end user the our for nine of capturing X-Tack, this and great a for These our the first by the almost accounts how audience. applications X-Tack. best that from participated and hosted XX insights in is product discussions the our are Storm and launch accounts, The the participated
in quarter. second the to advance our continue We launch
to and continue centers, introducing in will effective creating adoption with use a eye keen patterns. advance of buildings the XXXX the in rest new for second sustainable tools, a We driving the education quarter, in X-Tack launch
than has and in total pipeline X-Tack been $X working that potential procurement to team new sales. a sales of way on their Our a million are expanding and processes orders more managing worth focused hospital potential access are to is we and account
XXXX Turning is with XX% strength that surgical product have invasive bariatric an Balloon the that been more current solutions seen asset. and alone. franchise is worldwide excellent the than a it's for IGB to very potentially a will the said, to important we off QX, growth franchise effective NASH and of treatment designation as options, conditions. Orbera Apollo, say I on an diet are but very we the IGB events quarter. of IGB, than that, has and strategies breakthrough treatment past FDA solid announced exercise year-on-year for need for customer of the line. and years IGB medical a therapy is an job, with few believe the effective of this position first a That testament this years, over on Orbera underappreciated less the fundamentally back developed day changed the weight that, very validation clinical The options several still loss patients positioning in to of based this look we was strategic for My
label the We be designing designation, benefits maximize to clinical are a pursue the working that of including on will this next steps expansion. required trial to
end approved the discussions year. about to in are and the we We trial design CMS an have with and hope trial by of FDA the
demonstrating supported We the procedures. assigned physician for community. also X the I receive American that notification interesting to efforts, learn Association separate IGB that organizations CPT support widespread Codes Medical It the new Category in was
the quarter XX% effects for issued the XX% use achieved versus year the that has very of of QX growth a in driven I our over – see and field first And And Stefanie by we performance, resulted exciting ahead. for all over here for addition three look an endoscopy. a a the recommending to product IGB turning first COVID with to the that their together, we're growth value results with with in Taking forward pleased very Apollo. revenue therapeutic IGB practice enhance IGB. business year, the has work the first time at then accelerate in guidelines, foundation Stef? and three financial believe provide XXXX. franchise. some growth I'll smaller growth XXXX, leveraging that that, patients. the Association, – pleased to and developments the the in lead solid And quarter It's time, time, Apollo, to QX XX% I'm our cover we've results appropriate Even over lines Gastroenterological team start to ESS lingering here team turn detail. positive AGA with to energize of of American the the to at greater call and ultimately place that prior In these the of
